care.ai, NVIDIA collaborate on AI-powered hospital room solutions

Just days after launching a partnership with Google, care.ai has announced that it is now working with NVIDIA to improve patient care.

For this new collaboration, NVIDIA’s Jetson AI platform will be used to help power care.ai’s autonomous monitoring edge solutions. These edge sensors help protect patients from avoidable accidents by providing real-time data to healthcare providers.

“There is a great number of preventable incidents that occur within hospitals and nursing homes each year: falls, infections and protocol violations,” Chakri Toleti, founder and CEO of care.ai, said in a prepared statement. “As a leader in AI, NVIDIA was a clear choice for us as we built the world’s most advanced solution to these yet to be solved problems. Through this collaboration, we now have the ability to run our deep neural networks on devices while maintaining a small physical and energy footprint.”

“AI has the potential to improve healthcare across a range of areas, and ultimately help save lives,” Mona Flores, MD, global lead for hospitals and clinical partnerships at NVIDIA, said in the same statement. “Our Jetson platform provides unprecedented processing power to help care.ai’s application deliver more efficacious and efficient patient monitoring in healthcare.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.